China National Accord Medicines Corporation Ltd. First Quarterly Report 2017
China National Accord Medicines Corporation Ltd.
First Quarterly Report 2017
April 2017
1
China National Accord Medicines Corporation Ltd. First Quarterly Report 2017
Section I. Important Notes
Board of Directors and the Supervisory Committee of China National Accord
Medicines Corporation Ltd. (hereinafter referred to as the Company) and its
directors, supervisors and senior executives should guarantee the reality, accuracy
and completion of the quarterly report, there are no any fictitious statements,
misleading statements or important omissions carried in this report, and shall
take legal responsibilities, individual and/or joint.
All Directors are attended the Board Meeting for Quarterly Report deliberation.
Lin Zhaoxiong, person in charge of the Company, Wei Pingxiao, person in charge
of accounting works and Wang Ying, person in charge of accounting organ
(accounting officer) hereby confirm that the Financial Report of this Quarterly
Report is authentic, accurate and complete.
2
China National Accord Medicines Corporation Ltd. First Quarterly Report 2017
Section II. Company profile
I. Main accounting data and financial indexes
Whether it has retroactive adjustment or re-statement on previous accounting data for accounting policy changed and accounting error
correction or not
□ Yes √No
Changes of this period over
Current Period Same period of last year
same period of last year
Operating income (RMB) 10,222,459,812.55 10,312,188,572.41 -0.87%
Net profit attributable to shareholders of the
272,564,318.71 253,633,838.82 7.46%
listed company(RMB)
Net profit attributable to shareholders of
the listed company after deducting non- 271,249,398.43 192,733,022.25 40.74%
recurring gains and losses(RMB)
Net cash flow arising from operating
-502,263,276.11 10,756,298.46 -4,769.48%
activities(RMB)
Basic earnings per share (RMB/Share) 0.64 0.60 6.67%
Diluted earnings per share (RMB/Share) 0.64 0.60 6.67%
Weighted average ROE 3.17% 3.39% -0.22%
Changes of this period-end
At the end of the reporting
At the end of last year over same period-end of last
period
year
Total assets (RMB) 21,519,365,688.68 21,316,548,247.95 0.95%
Net assets attributable to shareholder of
8,722,715,598.24 8,452,426,863.52 3.20%
listed company (RMB)
Note: operating revenue a decrease of 0.87% on a year-on-year basis, mainly due to the data for same period of last year including
the first quarter of 2016 under the recombination of the subsidiary reset out; the Group has a material assets restructuring in 2016, the
data of profit statement and cash flow statement for same period of last year including the first quarter of 2016 under the
recombination of the subsidiary reset out; data of non-recurring profit and loss in the same period of last year including the current
gains/losses of subsidairy from period-begin to combination date, which arising from combination under the same control.
Items of non-recurring gains and losses
√ Applicable □ Not applicable
In RMB
Amount from year-begin to
Item Note
period-end
Revenue from fixed assets
Gains/losses from the disposal of non-current asset (including the
26,130.26 disposal from subsidiary Guoda
write-off that accrued for impairment of assets)
Pharmacy
3
China National Accord Medicines Corporation Ltd. First Quarterly Report 2017
Governmental subsidy reckoned into current gains/losses (not
Mainly due to the various special
including the subsidy enjoyed in quota or ration according to
2,177,604.94 grants received in the current
national standards, which are closely relevant to enterprise’s
period;
business)
Current net gains/losses of the
Current net gains/losses of the subsidiary from enterprise subsidiary from period-begin to
combination under the same control (from period-begin to -1,096.00 combination dated which
combination date) included by combination under
the same control
Mainly because the bad debts of
Reversal of impairment reserve for account receivable with receivables withdrawn alone in
1,025,550.60
separate impairment testing the previous years have been
taken back in the current period
Other non-operating income and expenditure except for the
-1,333,342.37
aforementioned items
Less: impact on income tax 79,035.33
Impact on minority shareholders’ equity (post-tax) 500,891.82
Total 1,314,920.28 --
Concerning the extraordinary profit (gain)/loss defined by Q&A Announcement No.1 on Information Disclosure for Companies
Offering Their Securities to the Public --- Extraordinary Profit/loss, and the items defined as recurring profit (gain)/loss according to
the lists of extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their
Securities to the Public --- Extraordinary Profit/loss, explain reasons
□ Applicable √ Not applicable
In reporting period, the Company has no particular about items defined as recurring profit (gain)/loss according to the lists of
extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their Securities to the
Public --- Extraordinary Profit/loss
II. Total number of shareholders at the end of this report period and top ten shareholders
1. Total number of common shareholders at the end of this report period and top ten common shareholders
In shares
Total preference shareholders
Total common shareholders
with voting rights recovered at
17,789 0
at the end of report period end of reporting period (if
applicable)
Top ten shareholders
Amount of
Shareholder’s Nature of Proportion of Amount of shares Number of share pledged/frozen
restricted shares
name shareholder shares held held State of share Amount
held
Sinopharm Group State-owned legal
56.06% 239,999,991 55,057,700
Co., Ltd. person
HTHK/CMG Foreign 2.04% 8,732,491
4
China National Accord Medicines Corporation Ltd. First Quarterly Report 2017
FSGUFP-CMG Corporation
FIRST STATE
CHINA
GROWTH FD
China Life
Insurance Co.,
Domestic non
Ltd. – tradition –
state-owned legal 1.50% 6,404,002
general insurance
person
products - 005L-
CT001 Shen
China National
Pharmaceutical State-owned legal
1.24% 5,323,043
Foreign Trade person
Corporation
TARGET Foreign
1.19% 5,087,517
VALUE FUND Corporation
GUOTAI
JUNAN
Foreign
SECURITIES(H 1.02% 4,379,257
Corporation
ONGKONG)
LIMITED
China Life
Insurance Co.,
Ltd. – tradition – Domestic non
general insurance state-owned legal 0.98% 4,199,772
products -018L- person
FH002
Shen
China Merchants
Bank Co., Ltd. –
Domestic non
Huitianfu
state-owned legal 0.95% 4,074,656
Medical Service
person
Flexi Mix Stock
Fund
Central Huijin State-owned legal
0.89% 3,804,400
Investment Ltd. person
Domestic non
CITIC Securities
state-owned legal 0.86% 3,681,300
Co., Ltd.
person
Top ten shareholders with unrestricted shares held
Shareholder’s name Amount of unrestricted shares held Type of shares
5
China National Accord Medicines Corporation Ltd. First Quarterly Report 2017
Type Amount
RMB ordinary
Sinopharm Group Co., Ltd. 184,942,291 184,942,291
shares
Domestically
HTHK/CMG FSGUFP-CMG FIRST
8,732,491 listed foreign 8,732,491
STATE CHINA GROWTH FD
shares
China Life Insurance Co., Ltd. –
RMB ordinary
tradition – general insurance 6,404,002 6,404,002
shares
products - 005L-CT001 Shen
China National Pharmaceutical RMB ordinary
5,323,043 5,323,043
Foreign Trade Corporation shares
Domestically
TARGET VALUE FUND 5,087,517 listed foreign 5,087,517
shares
GUOTAI JUNAN Domestically
SECURITIES(HONGKONG) 4,379,257 listed foreign 4,379,257
LIMITED shares
China Life Insurance Co., Ltd. –
RMB ordinary
tradition –general insurance products 4,199,772 4,199,772
shares
-018L-FH002 Shen
China Merchants Bank Co., Ltd. –
RMB ordinary
Huitianfu Medical Service Flexi Mix 4,074,656 4,074,656
shares
Stock Fund
RMB ordinary
Central Huijin Investment Ltd. 3,804,400 3,804,400
shares
RMB ordinary
CITIC Securities Co., Ltd. 3,681,300 3,681,300
shares
Explanation on associated It is unknown that there exists no associated relationship or belongs to the consistent actionist
relationship among the aforesaid among the above shareholders regulated by the Management Measure of Information
shareholders Disclosure on Change of Shareholding for Listed Companies.
Whether top ten common shareholders or top ten common shareholders with un-restrict shares held have a buy-back agreement dealing
in reporting period
□ Yes √ No
The top ten common shareholders or top ten common shareholders with un-restrict shares held of the Company have no buy-back
agreement dealing in reporting period.
2. Total shareholders with preferred stock held at Period-end and shares held by top ten shareholders with
preferred stock held
□ Applicable √ Not applicable
6
China National Accord Medicines Corporation Ltd. First Quarterly Report 2017
Section III. Significant Events
I. Particulars about material changes in items of main accounting statement and financial index
and explanations of reasons
√Applicable □Not applicable
1. Interest receivable: a decrease of 359,000 Yuan compared with the beginning of the period, with a growth rate of -79.66%, mainly
because savings in the Bank declined in the Period;
2. Other non-current assets: an increase of 57.086 million Yuan compared with the beginning of the period, with a growth rate of
60.31%, mainly because subscribed Medical Industry Fund in the period;
3. Wages payable: a decrease of 72.8905 million Yuan compared with the beginning of the period, with a growth rate of -37.35%,
mainly because employee’s wages accrual last year are provided in the period;
4. Other current liabililty: an increase of 51.0475 million Yuan compared with the beginning of the period, with a growth rate of
41,402.79%, mainly because certified input tax increased;
5. Other equity instruments：a decrease of 65.4950 million Yuan compared with the beginning of the period, with a growth rate of -
100.00%, mainly because unlisted shares last year were successfully issued and listed on 5 January 2017. Other equity instruments
adjust to share capital in the period;
6. Asseets impairment loss: a decrease of 4.0059 million Yuan on a year-on-year basis, with a growth rate of -93.60%, mainly due to
the reversal of bad debts and inventory falling price reserves;
7. Investment income: an increase of 61.1573 million Yuan on a year-on-year basis, with a growth rate of 622.15%, mainly because
part of the subsidiaries turns to jointly run business for restructuring last year, the investment income increased;
8. Non-operation revenue: a decrease of 4.8295 million Yuan on a year-on-year basis, with a growth rate of -59.00%, mainly because
part of subsidiaries reset-out for restructuring last year;
9. Non-operation expenditure: an increase of 2.2076 million Yuan on a year-on-year basis, with a growth rate of 794.20%, mainly due
to the fine for delaying payment;
10. Refunds of taxes: a decrease of 3.9955 million Yuan on a year-on-year basis, with a growth rate of -97.59%, mainly because part
of subsidiaries reset-out for restructuring last year;
11. Net cash flow from operating activities: a decrease of 513 million Yuan on a year-on-year basis, with a growth rate of -4,769.48%,
mainly because the cash payment growth over that of cash received;
12. Cash received from investment income: an increase of 424,500 Yuan on a year-on-year basis, mainly due to the entrusted loan
interest received from jointly run business in the Period while no such amount occurred at same period of last year;
13. Net cash received from disposal of fixed assets, intangible assets and other long-term assets: a decrease of 2.0907 million Yuan on
a year-on-year basis, with a growth rate of -94.19%, mainly because income from fixed assets disposal in the Period decline from a
year earlier;
14. Other cash received relating to investment activities: a decrease of 1391 million Yuan on a year-on-year basis, with a growth rate
of -94.19%, mainly because the subsidiary, replace after reorganization, has a decrease of capital pool business with its former parent
company on a year-on-year basis;
15. Sub-total of cash inflows from investing activities: a decrease of 1393 million Yuan on a year-on-year basis, with a growth rate of
-94.16%, mainly because the subsidiary, replace after reorganization, has a decrease of capital pool business with its former parent
company on a year-on-year basis;
16. Cash paid for the purchase and construction of fixed assets, intangible assets and other long-term assets: a decrease of
24.8648million Yuan on a year-on-year basis, with a growth rate of -39.82%, mainly because there were expenditure from Pingshan
7
China National Accord Medicines Corporation Ltd. First Quarterly Report 2017
Project at same period of last year while no such expenditure occurred in the period;
17. Cash paid for investment: an increase of 60 million Yuan on a year-on-year basis, mainly because subscribed Medical Industry
Fund in the period while no such amount occurred last period;
18. Net cash paid for obtaining subsidiary and other operation units: an increase of 10 million Yuan on a year-on-year basis, mainly
because the money for subscribing subsidiary’s equity are paid in the period;
19. Other cash paid relating to investment activities: a decrease of 984million Yuan on a year-on-year basis, with a growth rate of -
83.18%, mainly because the subsidiary, replace after reorganization, has a decrease of capital pool business with its former parent
company on a year-on-year basis;
20. Sub-total of cash outflows from investing activities: a decrease of 939 million Yuan on a year-on-year basis, with a growth rate of
-75.38%, mainly because the subsidiary, replace after reorganization, has a decrease of capital pool business with its former parent
company on a year-on-year basis;
21. Net cash flow from investment activities: a decrease of 454 million Yuan on a year-on-year basis, with a growth rate of -194.14%,
mainly because the subsidiary, replace after reorganization, has a decrease of capital pool business with its former parent company on
a year-on-year basis;
22. Cash received by absorbing investments: a decrease of 1.47 million Yuan on a year-on-year basis, with a growth rate of -100%,
mainly because there were investment received from minority shareholder at same period of last year while no such amount occurred
in the period;
23. Cash received from debts: a decrease of 51.7869 million Yuan on a year-on-year basis, with a growth rate of -36.91%, mainly
because bank loans received from bank declined from a year earlier;
24. Other cash received relating to financing activities: a decrease of 89.2832 million Yuan on a year-on-year basis, with a growth rate
of -79.70%, mainly because the financing money received in the Period decline from a year earlier;
25. Sub-total of cash inflows from financing activities: a decrease of 143 million Yuan on a year-on-year basis, with a growth rate of -
56.16%, mainly because the financing money received in the Period decline from a year earlier;
26. Cash paid for debt-payment: a decrease of 87.775 million Yuan on a year-on-year basis, with a growth rate of -56.93%, mainly
because cash paid for debts declined from a year earlier;
27. Cash paid for distribution of dividend, profit or interest payment: a decrease of 16.1005 million Yuan on a year-on-year basis, with
a growth rate of -43.88%, mainly because the company combine-in from restructuring have dividend distribution at same period of last
year, while no such amount occurred in the Period;
28. Other cash paid relating to financing activities: a decrease of 5.7351million Yuan on a year-on-year basis, with a growth rate of -
70.91%, mainly because tail payment for acquiring minority’s shares are paid at same period of last year while no such amount occurred
in the period;
29. Sub-total of cash outflows from financing activities: a decrease of 110 million Yuan on a year-on-year basis, with a growth rate of
-55.09%, mainly because payment for debts declined from a year earlier;
30. Net cash flow from financing activities: a decrease of 32.9294 million Yuan on a year-on-year basis, with a growth rate of -60.04%,
mainly because the financing money received in the Period decline from a year earlier;
31. Net increase in cash and cash equivalents: a decrease of 1000 million Yuan on a year-on-year basis, with a growth rate of -333.94%,
mainly because net cash flow from operation and investment activities decline from a year earlier.
II. Analysis and explanation of significant events and their influence and solutions
√Applicable □Not applicable
Sinopharm Accord continues to promoting relvant major restructuring in the Peirod, follow-up progres can be found in the notices as:
Interim report disclosure website query
Overview of important matters Date of disclosure
index
8
China National Accord Medicines Corporation Ltd. First Quarterly Report 2017
Asset sales, stock issuance, asset purchase
Registration listing for new shares of by cash, raised supporting funds and
2017-01-04
material assets restructuring related transactions and listing particulars
of new shares released on Juchao website
Material assets restructuring completion-
Progress of the material assets restructuring
real estate transfer registration procedures
2017-02-28 of Sinopharm Accord (Notice: 2017-11)
for Pingshan Base, relevant real estate
released on Juchao website
registered under the name of Shyndec
The counterpart-Shanghai Shyndec
Pharmaceutical Co., Ltd. completed Progress of the material assets restructuring
registered procedures for the private 2017-03-09 of Sinopharm Accord (Notice: 2017-12)
placement shares, relevant shares are released on Juchao website
restricted shares.
III. Commitments completed in Period and those without completed till end of the Period from actual
controller, shareholders, related parties, purchaser and companies
□ Applicable √ Not applicable
The Company has no commitments completed in Period and those without completed till end of the Period from
actual controller, shareholders, related parties, purchaser and companies.
IV. Predict of the business performance from January to June 2017
Warnings and reasons of the predict that the cumulative net profit from the begin of the year to the end of next report period may be
loss or have great changes comparing with the same period of last year
□Applicable √Not applicable
V. Securities Investment
□ Applicable √ Not applicable
No security investment in the Period.
VI. Derivative investment
□ Applicable √ Not applicable
No derivative investment in the Period.
VII. Registration form for receiving research, communication and interview in the report period
□Applicable √Not applicable
The Company had no receiving research, communication or interview in the report period.
VIII. Guarantee outside against the regulation
□Applicable √Not applicable
The Company had no guarantee outside against the regulation in the period.
9
China National Accord Medicines Corporation Ltd. First Quarterly Report 2017
IX. Non-operational fund occupation from controlling shareholders and its related party
□ Applicable √ Not applicable
The Company had no non-operational fund occupation form controlling shareholders and its related party in the period.
10
China National Accord Medicines Corporation Ltd. First Quarterly Report 2017
Section IV. Financial Statement
I. Financial statement
1. Consolidate balance sheet
Prepared by China National Accord Medicines Corporation Ltd.
2017-03-31
In RMB
Item Balance at period-end Balance at period-begin
Current assets:
Monetary funds 2,796,099,484.57 3,519,961,564.93
Settlement provisions
Capital lent
Financial liability measured by fair
value and with variation reckoned into
current gains/losses
Derivative financial assets
Notes receivable 1,110,261,545.95 1,504,000,909.21
Accounts receivable 9,298,502,123.27 7,654,225,510.89
Accounts paid in advance 394,303,159.43 424,867,581.80
Insurance receivable
Reinsurance receivables
Contract reserve of reinsurance
receivable
Interest receivable 91,676.79 450,722.67
Dividend receivable
Other receivables 393,082,415.96 478,573,423.62
Purchase restituted finance asset
Inventories 3,685,717,264.10 4,049,482,529.71
Divided into assets held for sale
Non-current asset due within one
year
Other current assets 48,384,429.30 57,209,263.04
Total current assets 17,726,442,099.37 17,688,771,505.87
Non-current assets:
11
China National Accord Medicines Corporation Ltd. First Quarterly Report 2017
Loans and payments on behalf
Finance asset available for sales 13,685,760.00 13,685,760.00
Held-to-maturity investment
Long-term account receivable
Long-term equity investment 1,482,700,735.67 1,413,034,165.56
Investment property 164,447,228.21 166,715,848.80
Fixed assets 514,005,852.60 487,009,600.10
Construction in progress 42,694,516.48 47,063,868.49
Engineering material
Disposal of fixed asset
Productive biological asset
Oil and gas asset
Intangible assets 318,541,349.78 320,435,400.89
Expense on Research and
Development
Goodwill 827,955,081.85 823,890,174.21
Long-term expenses to be
209,134,291.21 188,377,725.64
apportioned
Deferred income tax asset 68,023,263.30 72,914,722.30
Other non-current asset 151,735,510.21 94,649,476.09
Total non-current asset 3,792,923,589.31 3,627,776,742.08
Total assets 21,519,365,688.68 21,316,548,247.95
Current liabilities:
Short-term loans 1,538,602,204.92 1,512,713,629.95
Loan from central bank
Absorbing deposit and interbank
deposit
Capital borrowed
Financial liability measured by fair
value and with variation reckoned into
current gains/losses
Derivative financial liability
Notes payable 2,090,361,751.97 2,406,642,582.86
Accounts payable 7,004,411,804.71 6,701,558,514.10
Accounts received in advance 157,548,327.24 163,450,365.92
Selling financial asset of
repurchase
Commission charge and
12
China National Accord Medicines Corporation Ltd. First Quarterly Report 2017
commission payable
Wage payable 122,247,574.42 195,138,079.85
Taxes payable 189,359,892.21 187,043,717.52
Interest payable 5,368,157.41 6,956,463.02
Dividend payable 10,346,753.38 8,483,370.21
Other accounts payable 846,031,951.53 917,193,911.34
Reinsurance payables
Insurance contract reserve
Security trading of agency
Security sales of agency
Divided into liability held for sale
Non-current liabilities due within 1
35,032,221.22 36,411,339.96
year
Other current liabilities 51,170,775.48 123,294.77
Total current liabilities 12,050,481,414.49 12,135,715,269.50
Non-current liabilities:
Long-term loans
Bonds payable
Including: preferred stock
Perpetual capital
securities
Long-term account payable 14,863,880.39 14,616,598.34
Long-term wages payable 1,664,599.89 1,722,599.89
Special accounts payable 800,000.00 800,000.00
Accrual liabilities
Deferred income 122,201,835.27 123,953,462.81
Deferred income tax liabilities 75,437,750.54 76,535,704.01
Other non-current liabilities 45,427,343.31 45,427,343.31
Total non-current liabilities 260,395,409.40 263,055,708.36
Total liabilities 12,310,876,823.89 12,398,770,977.86
Owner’s equity:
Share capital 428,126,983.00 362,631,943.00
Other equity instrument 65,495,040.00
Including: preferred stock
Perpetual capital
securities
13
China National Accord Medicines Corporation Ltd. First Quarterly Report 2017
Capital public reserve 3,151,518,024.92 3,152,718,024.92
Less: Inventory shares
Other comprehensive income
Reasonable reserve
Surplus public reserve 181,315,971.50 181,315,971.50
Provision of general risk
Retained profit 4,961,754,618.82 4,690,265,884.10
Total owner’s equity attributable to
8,722,715,598.24 8,452,426,863.52
parent company
Minority interests 485,773,266.55 465,350,406.57
Total owner’s equity 9,208,488,864.79 8,917,777,270.09
Total liabilities and owner’s equity 21,519,365,688.68 21,316,548,247.95
Legal Representative: Lin Zhaoxiong
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institute: Wang Ying
2. Balance Sheet of Parent Company
In RMB
Item Closing balance Opening balance
Current assets:
Monetary funds 761,845,851.83 1,342,041,409.86
Financial liability measured by fair
value and with variation reckoned into
current gains/losses
Derivative financial liability
Notes receivable 12,305,370.91 79,868,867.49
Accounts receivable 620,235,997.19 397,351,577.24
Account paid in advance 484,455.35 2,135,439.82
Interest receivable 2,417,884.05 2,029,125.06
Dividends receivable 207,042.57
Other receivables 1,989,707,656.30 1,801,567,851.50
Inventories 174,986,104.03 184,708,273.76
Divided into assets held for sale
Non-current assets maturing within
one year
Other current assets 25,357,594.29 6,937,946.90
Total current assets 3,587,547,956.52 3,816,640,491.63
14
China National Accord Medicines Corporation Ltd. First Quarterly Report 2017
Non-current assets:
Available-for-sale financial assets
Held-to-maturity investments
Long-term receivables
Long-term equity investments 5,999,850,052.49 5,914,542,602.10
Investment property 3,369,815.00 3,571,809.38
Fixed assets 15,899,862.35 16,555,996.92
Construction in progress
Project materials
Disposal of fixed assets
Productive biological assets
Oil and natural gas assets
Intangible assets 1,382,080.82 1,534,730.15
Research and development costs
Goodwill
Long-term deferred expenses 6,448,230.31 6,645,211.13
Deferred income tax assets 2,811,216.63 2,869,931.88
Other non-current assets 69,545,809.37 9,859,840.00
Total non-current assets 6,099,307,066.97 5,955,580,121.56
Total assets 9,686,855,023.49 9,772,220,613.19
Current liabilities:
Short-term borrowings 110,000,000.00 50,000,000.00
Financial liability measured by fair
value and with variation reckoned into
current gains/losses
Derivative financial liability
Notes payable 227,888,785.81 334,383,191.54
Accounts payable 463,655,551.82 391,726,381.93
Accounts received in advance 5,807,116.26 2,997,964.16
Wage payable 22,511,539.15 30,618,183.84
Taxes payable 11,409,348.01 3,308,582.29
Interest payable 87,520.75 37,801.50
Dividend payable
Other accounts payable 887,180,750.29 1,100,143,593.55
15
China National Accord Medicines Corporation Ltd. First Quarterly Report 2017
Divided into liability held for sale
Non-current liabilities due within 1
31,600,000.00 31,600,000.00
year
Other current liabilities 5,050,140.36 123,294.77
Total current liabilities 1,765,190,752.45 1,944,938,993.58
Non-current liabilities:
Long-term loans
Bonds payable
Including: preferred stock
Perpetual capital
securities
Long-term account payable
Long-term wages payable 26,000.00 26,000.00
Special accounts payable 800,000.00 800,000.00
Projected liabilities
Deferred income 1,570,000.00 1,570,000.00
Deferred income tax liabilities 3,773,319.00 3,773,319.00
Other non-current liabilities
Total non-current liabilities 6,169,319.00 6,169,319.00
Total liabilities 1,771,360,071.45 1,951,108,312.58
Owners’ equity:
Share capita 428,126,983.00 362,631,943.00
Other equity instrument 65,495,040.00
Including: preferred stock
Perpetual capital
securities
Capital public reserve 4,381,845,619.03 4,381,845,619.03
Less: Inventory shares
Other comprehensive income
Reasonable reserve
Surplus reserve 181,315,971.50 181,315,971.50
Retained profit 2,924,206,378.51 2,829,823,727.08
Total owner’s equity 7,915,494,952.04 7,821,112,300.61
Total liabilities and owner’s equity 9,686,855,023.49 9,772,220,613.19
16
China National Accord Medicines Corporation Ltd. First Quarterly Report 2017
3. Consolidated Profit Statement
In RMB
Item Current Period Last Period
I. Total operating income 10,222,459,812.55 10,312,188,572.41
Including: Operating income 10,222,459,812.55 10,312,188,572.41
Interest income
Insurance gained
Commission charge and commission
income
II. Total operating cost 9,929,024,160.13 9,974,675,464.87
Including: Operating cost 9,158,010,239.31 9,145,010,801.79
Interest expense
Commission charge and commission
expense
Cash surrender value
Net amount of expense of
compensation
Net amount of withdrawal of
insurance contract reserve
Bonus expense of guarantee slip
Reinsurance expense
Operating tax and extras 29,737,745.69 27,429,980.11
Sales expenses 548,629,093.08 548,457,922.97
Administration expenses 170,428,020.23 219,502,847.09
Financial expenses 21,945,189.25 29,994,098.93
Losses of devaluation of asset 273,872.57 4,279,813.98
Add: Changing income of fair
value(Loss is listed with “-”)
Investment income (Loss is listed
70,987,332.61 9,830,026.19
with “-”)
Including: Investment income on
70,987,332.61 9,830,026.19
affiliated company and joint venture
Exchange income (Loss is listed
with “-”)
III. Operating profit (Loss is listed with
364,422,985.03 347,343,133.73
“-”)
17
China National Accord Medicines Corporation Ltd. First Quarterly Report 2017
Add: Non-operating income 3,356,001.50 8,185,484.31
Including: Disposal gains of
44,428.66 1,489,651.94
non-current asset
Less: Non-operating expense 2,485,608.67 277,968.89
Including: Disposal loss of
18,298.40 56,642.55
non-current asset
IV. Total Profit (Loss is listed with “-”) 365,293,377.86 355,250,649.15
Less: Income tax expense 70,280,239.83 80,232,830.67
V. Net profit (Net loss is listed with “-”) 295,013,138.03 275,017,818.48
Net profit attributable to owner’s of
272,564,318.71 253,633,838.82
parent company
Minority shareholders’ gains and
22,448,819.32 21,383,979.66
losses
VI. Net after-tax of other comprehensive
income
Net after-tax of other comprehensive
income attributable to owners of parent
company
(I) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1. Changes as a result of re-
measurement of net defined benefit plan
liability or asset
2. Share of the other
comprehensive income of the investee
accounted for using equity method which
will not be reclassified subsequently to
profit and loss
(II) Other comprehensive income
items which will be reclassified
subsequently to profit or loss
1. Share of the other
comprehensive income of the investee
accounted for using equity method which
will be reclassified subsequently to profit
or loss
2. Gains or losses arising
from changes in fair value of available-
for-sale financial assets
18
China National Accord Medicines Corporation Ltd. First Quarterly Report 2017
3. Gains or losses arising
from reclassification of held-to-maturity
investment as available-for-sale financial
assets
4. The effect hedging portion
of gains or losses arising from cash flow
hedging instruments
5. Translation differences
arising on translation of foreign currency
financial statements
6. Other
Net after-tax of other comprehensive
income attributable to minority
shareholders
VII. Total comprehensive income 295,013,138.03 275,017,818.48
Total comprehensive income
272,564,318.71 253,633,838.82
attributable to owners of parent Company
Total comprehensive income
22,448,819.32 21,383,979.66
attributable to minority shareholders
VIII. Earnings per share:
(i) Basic earnings per share 0.64 0.60
(ii) Diluted earnings per share 0.64 0.60
Enterprise combine under the same control in the Period, the combined party realized net profit of -1,096.00 Yuan before combination,
and realized -91,026.08 Yuan at last period for combined party
Legal Representative: Lin Zhaoxiong
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institute: Wang Ying
4. Profit Statement of Parent Company
In RMB
Item Current Period Last Period
I. Operating income 802,057,016.78 749,904,714.81
Less: Operating cost 769,324,785.10 722,509,130.22
Operating tax and extras 1,519,528.19 1,619,254.47
Sales expenses 12,395,531.55 10,022,247.07
Administration expenses 13,154,355.35 11,851,745.82
Financial expenses -18,888,226.18 -15,476,187.80
Losses of devaluation of asset -110,682.96 181,694.80
19
China National Accord Medicines Corporation Ltd. First Quarterly Report 2017
Add: Changing income of fair
value(Loss is listed with “-”)
Investment income (Loss is
76,265,472.96 10,060,782.41
listed with “-”)
Including: Investment income
76,265,472.96 10,060,782.41
on affiliated company and joint venture
II. Operating profit (Loss is listed
100,927,198.69 29,257,612.64
with “-”)
Add: Non-operating income 648,816.60 125,086.40
Including: Disposal gains of
1,087.38
non-current asset
Less: Non-operating expense 1,011,760.15
Including: Disposal loss of
non-current asset
III. Total Profit (Loss is listed with
100,564,255.14 29,382,699.04
“-”)
Less: Income tax expense 6,181,603.71 4,830,479.16
IV. Net profit (Net loss is listed with
94,382,651.43 24,552,219.88
“-”)
V. Net after-tax of other comprehensive
income
(I) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1. Changes as a result of re-
measurement of net defined benefit plan
liability or asset
2. Share of the other
comprehensive income of the investee
accounted for using equity method
which will not be reclassified
subsequently to profit and loss
(II) Other comprehensive income
items which will be reclassified
subsequently to profit or loss
1. Share of the other
comprehensive income of the investee
accounted for using equity method
which will be reclassified subsequently
to profit or loss
20
China National Accord Medicines Corporation Ltd. First Quarterly Report 2017
2. Gains or losses arising
from changes in fair value of available-
for-sale financial assets
3. Gains or losses arising
from reclassification of held-to-maturity
investment as available-for-sale
financial assets
4. The effect hedging
portion of gains or losses arising from
cash flow hedging instruments
5. Translation differences
arising on translation of foreign
currency financial statements
6. Other
VI. Total comprehensive income 94,382,651.43 24,552,219.88
VII. Earnings per share:
(i) Basic earnings per share
(ii) Diluted earnings per share
5. Consolidated Cash Flow Statement
In RMB
Item Current Period Last Period
I. Cash flows arising from operating
activities:
Cash received from selling
commodities and providing labor 10,328,284,481.94 9,781,000,149.62
services
Net increase of customer deposit
and interbank deposit
Net increase of loan from central
bank
Net increase of capital borrowed
from other financial institution
Cash received from original
insurance contract fee
Net cash received from reinsurance
business
Net increase of insured savings and
21
China National Accord Medicines Corporation Ltd. First Quarterly Report 2017
investment
Net increase of amount from
disposal financial assets that measured
by fair value and with variation
reckoned into current gains/losses
Cash received from interest,
commission charge and commission
Net increase of capital borrowed
Net increase of returned business
capital
Write-back of tax received 98,628.11 4,094,137.76
Other cash received concerning
207,536,266.55 170,589,871.87
operating activities
Subtotal of cash inflow arising from
10,535,919,376.60 9,955,684,159.25
operating activities
Cash paid for purchasing
commodities and receiving labor 9,820,844,639.93 8,780,371,963.70
service
Net increase of customer loans and
advances
Net increase of deposits in central
bank and interbank
Cash paid for original insurance
contract compensation
Cash paid for interest, commission
charge and commission
Cash paid for bonus of guarantee
slip
Cash paid to/for staff and workers 479,482,361.89 511,770,579.28
Taxes paid 295,430,548.56 276,644,961.76
Other cash paid concerning
442,425,102.33 376,140,356.05
operating activities
Subtotal of cash outflow arising from
11,038,182,652.71 9,944,927,860.79
operating activities
Net cash flows arising from operating
-502,263,276.11 10,756,298.46
activities
II. Cash flows arising from investing
activities:
Cash received from recovering
22
China National Accord Medicines Corporation Ltd. First Quarterly Report 2017
investment
Cash received from investment
424,502.22
income
Net cash received from disposal of
fixed, intangible and other long-term 129,038.95 2,219,699.07
assets
Net cash received from disposal of
subsidiaries and other units
Other cash received concerning
85,815,179.38 1,476,658,653.38
investing activities
Subtotal of cash inflow from investing
86,368,720.55 1,478,878,352.45
activities
Cash paid for purchasing fixed,
37,572,554.85 62,437,396.54
intangible and other long-term assets
Cash paid for investment 60,000,000.00
Net increase of mortgaged loans
Net cash received from
10,000,000.00
subsidiaries and other units obtained
Other cash paid concerning
198,944,422.63 1,182,600,150.11
investing activities
Subtotal of cash outflow from investing
306,516,977.48 1,245,037,546.65
activities
Net cash flows arising from investing
-220,148,256.93 233,840,805.80
activities
III. Cash flows arising from financing
activities
Cash received from absorbing
1,470,000.00
investment
Including: Cash received from
absorbing minority shareholders’ 1,470,000.00
investment by subsidiaries
Cash received from loans 88,522,962.94 140,309,896.11
Cash received from issuing bonds
Other cash received concerning
22,743,050.43 112,026,204.05
financing activities
Subtotal of cash inflow from financing
111,266,013.37 253,806,100.16
activities
Cash paid for settling debts 66,403,745.30 154,178,778.20
23
China National Accord Medicines Corporation Ltd. First Quarterly Report 2017
Cash paid for dividend and profit
20,595,737.67 36,696,237.89
distributing or interest paying
Including: Dividend and profit of
minority shareholder paid by 508,903.35 12,016,140.85
subsidiaries
Other cash paid concerning
2,353,233.82 8,088,355.36
financing activities
Subtotal of cash outflow from financing
89,352,716.79 198,963,371.45
activities
Net cash flows arising from financing
21,913,296.58 54,842,728.71
activities
IV. Influence on cash and cash
equivalents due to fluctuation in
exchange rate
V. Net increase of cash and cash
-700,498,236.46 299,439,832.97
equivalents
Add: Balance of cash and cash
3,150,915,425.49 2,164,444,441.33
equivalents at the period -begin
VI. Balance of cash and cash
2,450,417,189.03 2,463,884,274.30
equivalents at the period -end
6. Cash Flow Statement of Parent Company
In RMB
Item Current Period Last Period
I. Cash flows arising from operating
activities:
Cash received from selling
commodities and providing labor 742,518,400.20 649,815,583.17
services
Write-back of tax received
Other cash received concerning
7,196,336.45 7,378,429.80
operating activities
Subtotal of cash inflow arising from
749,714,736.65 657,194,012.97
operating activities
Cash paid for purchasing
commodities and receiving labor 802,517,675.95 660,517,729.80
service
Cash paid to/for staff and workers 25,437,740.17 21,139,613.30
24
China National Accord Medicines Corporation Ltd. First Quarterly Report 2017
Taxes paid 31,457,445.98 12,632,832.46
Other cash paid concerning
5,269,455.38 3,957,308.12
operating activities
Subtotal of cash outflow arising from
864,682,317.48 698,247,483.68
operating activities
Net cash flows arising from operating
-114,967,580.83 -41,053,470.71
activities
II. Cash flows arising from investing
activities:
Cash received from recovering
investment
Cash received from investment
18,996,884.57 17,461,541.74
income
Net cash received from disposal of
fixed, intangible and other long-term
assets
Net cash received from disposal of
subsidiaries and other units
Other cash received concerning
628,959,200.00 524,540,000.00
investing activities
Subtotal of cash inflow from investing
647,956,084.57 542,001,541.74
activities
Cash paid for purchasing fixed,
2,112,339.07 16,955,491.97
intangible and other long-term assets
Cash paid for investment 60,000,000.00
Net cash received from
10,000,000.00
subsidiaries and other units
Other cash paid concerning
962,127,450.00 551,283,252.00
investing activities
Subtotal of cash outflow from investing
1,034,239,789.07 568,238,743.97
activities
Net cash flows arising from investing
-386,283,704.50 -26,237,202.23
activities
III. Cash flows arising from financing
activities
Cash received from absorbing
investment
Cash received from loans 10,000,000.00 80,100,000.00
25
China National Accord Medicines Corporation Ltd. First Quarterly Report 2017
Cash received from issuing bonds
Other cash received concerning
2,494,200,152.44 1,356,395,860.16
financing activities
Subtotal of cash inflow from financing
2,504,200,152.44 1,436,495,860.16
activities
Cash paid for settling debts 10,000,000.00 80,100,000.00
Cash paid for dividend and profit
1,542,929.92 2,805,513.22
distributing or interest paying
Other cash paid concerning
2,571,601,495.22 1,280,165,006.05
financing activities
Subtotal of cash outflow from financing
2,583,144,425.14 1,363,070,519.27
activities
Net cash flows arising from financing
-78,944,272.70 73,425,340.89
activities
IV. Influence on cash and cash
equivalents due to fluctuation in
exchange rate
V. Net increase of cash and cash
-580,195,558.03 6,134,667.95
equivalents
Add: Balance of cash and cash
1,342,041,409.86 429,437,078.35
equivalents at the period -begin
VI. Balance of cash and cash
761,845,851.83 435,571,746.30
equivalents at the period -end
II. Audit report
Whether the first quarterly report had been audited or not
□ Yes √ No
The first quarterly report of the Company had not been audited.
26
